Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PPAR alpha · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| PPAR alpha | DRUG | - |
| Hydrochlorothiazide | DRUG | - |
| Placebo | DRUG | - |
| atorvastatin | DRUG | - |
Inclusion Criteria: 1. Are men and women between 18 and 70 years of age, inclusive 2. Have given signed informed consent to participate in this study 3. Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy) Exclusion Criteria: 1. Secondary o...
Top 7 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Enlicitide |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran, Muvalaplin |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Pelacarsen |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | Obicetrapib |
| AstraZeneca PLC | AZN | 2 | PHASE2 | Rosuvastatin, AZD0780, AZD4954 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
PPAR alpha is an investigational small molecule being studied for cardiovascular conditions, including hypercholesterolemia, mild hypertension, and dyslipidemia. It has completed Phase 2 clinical trials in these indications. The drug is not approved and remains in clinical development.
PPAR alpha is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY. The company has conducted Phase 2 clinical trials of the drug for cardiovascular indications.
PPAR alpha is in Phase 2 clinical development. It has completed Phase 2 trials in dyslipidemia, hypercholesterolemia, and mild hypertension. The drug is investigational and has not been approved for any use.
PPAR alpha has completed three Phase 2 trials. NCT00116519 studied the drug in people with dyslipidemia in the United States. NCT00133380 studied it in people with high cholesterol in the United States. NCT00374855 studied it in people with mild hypertension in Sweden.
PPAR alpha is the name used for this investigational drug in clinical trials. No alternative names have been reported for this asset. It is a small molecule being studied for cardiovascular conditions.